ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $993,016 | $1,716,413 | $1,233,603 | $1,033,417 |
| - Cash | $59,557 | $51,540 | $39,864 | $50,817 |
| + Debt | $1,532 | $1,661 | $73 | $42 |
| Enterprise Value | $934,991 | $1,666,534 | $1,193,812 | $982,642 |
| Revenue | $32,501 | $15,717 | $7,973 | $86,581 |
| % Growth | 106.8% | 97.1% | -90.8% | – |
| Gross Profit | $24,310 | $10,733 | $3,927 | $82,689 |
| % Margin | 74.8% | 68.3% | 49.3% | 95.5% |
| EBITDA | -$48,799 | -$44,604 | -$36,897 | $47,226 |
| % Margin | -150.1% | -283.8% | -462.8% | 54.5% |
| Net Income | -$51,151 | -$44,883 | -$33,940 | $49,934 |
| % Margin | -157.4% | -285.6% | -425.7% | 57.7% |
| EPS Diluted | -0.52 | -0.46 | -0.35 | 0.51 |
| % Growth | -13% | -31.4% | -168.6% | – |
| Operating Cash Flow | -$47,047 | -$39,592 | -$40,742 | $42,004 |
| Capital Expenditures | -$197 | -$51 | -$91 | -$302 |
| Free Cash Flow | -$47,244 | -$39,643 | -$40,833 | $41,702 |